Zepaer Abudureheman MBBA , Tao Zhu MBBA , Dengyao Liu M.D., Ph.D.
{"title":"MSOR3 Presentation Time: 5:10 PM","authors":"Zepaer Abudureheman MBBA , Tao Zhu MBBA , Dengyao Liu M.D., Ph.D.","doi":"10.1016/j.brachy.2024.08.037","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>The study aimed to evaluate the combined efficacy of systemic therapy and iodine-125 seed implantation as a local treatment in patients with oligometastatic non-small cell lung cancer (NSCLC), defined by ≤3 metastatic organs and ≤5 metastatic lesions, and to identify factors that influence patient outcomes.</div></div><div><h3>Materials and Methods</h3><div>A retrospective review was conducted of 40 patients with oligometastatic NSCLC treated from January 2018 to June 2023 at our institution. Patients were divided into Group A (n=20), receiving both systemic therapy and iodine-125 seed implantation, and Group B (n=20), treated with systemic therapy alone. The primary outcome was progression-free survival (PFS), with overall survival (OS) serving as a secondary outcome. Survival analysis for PFS and OS was performed using Kaplan-Meier curves, with the Log-rank test for intergroup comparisons, and Cox regression analysis was used for univariate and multivariate analyses.</div></div><div><h3>Results</h3><div>The median PFS for Group A was 14.9 months (95% CI: 12.8-17.0), which was significantly longer than the 6.9 months (95% CI: 4.7-9.1) for Group B (HR=6.50, 95% CI: 4.60-9.20). The median OS was 28.7 months (95% CI: 19.5-37.9) for Group A, surpassing the 17.0 months (95% CI: 13.5-20.5) for Group B (HR=1.60, 95% CI: 1.05-2.40). Multivariate analysis highlighted intracranial metastasis as a significant risk factor for PFS. Influential factors for OS included oligometastatic status, the presence of brain metastases, histologic subtype, the use of immune checkpoint inhibitors (ICIs), driver mutations, anti-angiogenic treatments, and the implementation of iodine-125 seed implantation for local therapy.</div></div><div><h3>Conclusion</h3><div>In patients with oligometastatic NSCLC and stable primary lesions, the integration of systemic therapy with iodine-125 seed implantation markedly improves PFS and OS compared to systemic therapy alone. This underscores the value of iodine-125 seed implantation in the comprehensive treatment strategy, highlighting its significant role in enhancing patient survival outcomes.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brachytherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1538472124001739","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
The study aimed to evaluate the combined efficacy of systemic therapy and iodine-125 seed implantation as a local treatment in patients with oligometastatic non-small cell lung cancer (NSCLC), defined by ≤3 metastatic organs and ≤5 metastatic lesions, and to identify factors that influence patient outcomes.
Materials and Methods
A retrospective review was conducted of 40 patients with oligometastatic NSCLC treated from January 2018 to June 2023 at our institution. Patients were divided into Group A (n=20), receiving both systemic therapy and iodine-125 seed implantation, and Group B (n=20), treated with systemic therapy alone. The primary outcome was progression-free survival (PFS), with overall survival (OS) serving as a secondary outcome. Survival analysis for PFS and OS was performed using Kaplan-Meier curves, with the Log-rank test for intergroup comparisons, and Cox regression analysis was used for univariate and multivariate analyses.
Results
The median PFS for Group A was 14.9 months (95% CI: 12.8-17.0), which was significantly longer than the 6.9 months (95% CI: 4.7-9.1) for Group B (HR=6.50, 95% CI: 4.60-9.20). The median OS was 28.7 months (95% CI: 19.5-37.9) for Group A, surpassing the 17.0 months (95% CI: 13.5-20.5) for Group B (HR=1.60, 95% CI: 1.05-2.40). Multivariate analysis highlighted intracranial metastasis as a significant risk factor for PFS. Influential factors for OS included oligometastatic status, the presence of brain metastases, histologic subtype, the use of immune checkpoint inhibitors (ICIs), driver mutations, anti-angiogenic treatments, and the implementation of iodine-125 seed implantation for local therapy.
Conclusion
In patients with oligometastatic NSCLC and stable primary lesions, the integration of systemic therapy with iodine-125 seed implantation markedly improves PFS and OS compared to systemic therapy alone. This underscores the value of iodine-125 seed implantation in the comprehensive treatment strategy, highlighting its significant role in enhancing patient survival outcomes.
期刊介绍:
Brachytherapy is an international and multidisciplinary journal that publishes original peer-reviewed articles and selected reviews on the techniques and clinical applications of interstitial and intracavitary radiation in the management of cancers. Laboratory and experimental research relevant to clinical practice is also included. Related disciplines include medical physics, medical oncology, and radiation oncology and radiology. Brachytherapy publishes technical advances, original articles, reviews, and point/counterpoint on controversial issues. Original articles that address any aspect of brachytherapy are invited. Letters to the Editor-in-Chief are encouraged.